Related Experiment Video

Updated: May 30, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Pharmacogenetics of oral antidiabetic treatment

Z Schroner1, M Javorsky, M Kozarova

  • 1Department of Internal Medicine 4, Center of Excellence for the Study of Atherosclerosis, Faculty of Medicine, Safarik University, Kosice, Slovakia. zbynek.schroner@gmail.com

Bratislavske Lekarske Listy
|August 26, 2011
PubMed

Insights

Genetic variations influence how well oral antidiabetic drugs (OADs) work for type 2 diabetes (T2D) patients. Understanding these drug-genotype interactions can lead to personalized T2D therapies.

Area of Science:

  • Pharmacogenetics
  • Genetics
  • Endocrinology

Background:

  • Oral antidiabetic drugs (OADs) are first-line treatments for type 2 diabetes (T2D) after lifestyle changes.
  • OADs include insulin secretagogues (like sulfonylureas) and insulin sensitizers (metformin, glitazones).
  • Individual genetic makeup can affect OAD efficacy and risk of treatment failure.

Purpose of the Study:

  • To review the impact of gene polymorphisms on the effectiveness of oral antidiabetic drugs.
  • To explore drug-genotype interactions in type 2 diabetes pharmacogenetics.
  • To highlight potential for personalized medicine in T2D treatment.

Main Methods:

  • Review of pharmacogenetic studies on OADs.
  • Analysis of gene polymorphisms (KCNJ11, ABCC8, TCF7L2, PPARG, APM1, LPL) and their association with OAD response.
  • Examination of drug-genotype interactions for sulfonylureas, metformin, and glitazones.

Main Results:

  • KCNJ11 and ABCC8 gene polymorphisms affect sulfonylurea (SU) efficacy and failure risk.
  • TCF7L2 gene polymorphism influences secondary SU drug failure in T2D.
  • PPARG, APM1, and LPL gene variations impact glitazone and metformin treatment outcomes.

Conclusions:

  • Drug-genotype interactions are significant in OAD treatment for T2D.
  • Identifying these interactions can guide the selection of "patient-tailored therapy".
  • Pharmacogenetics holds promise for optimizing T2D management and improving patient outcomes.

Related Concept Videos

Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...